New technologies at Medtech Startups, November 2014

Below is a list of the technologies under development at companies recently identified and included in the Medtech Startups Database.

  • Handheld ultrasound, MRI imaging device.
  • Needle-free injection drug delivery.
  • Lenses designed to correct imbalance between eyes and brain that cause certain migraines.
  • Continuous blood glucose monitoring in diabetes.
  • Customized prosthetic aortic valve.
  • Cystoscope-implanted, stent-like device to treat urinary obstruction associated with benign prostatic hypertrophy.
  • Endovascular treatment for abdominal aortic aneurysm.
  • Respiratory therapy device based on “high frequency chest wall oscillation” for treatment of COPD, other respiratory disorders.
  • Treatment of arrhythmia.
  • Medical device commercialization company active in cardiovascular care, tissue ablation, medical infusions, hand surgery and laparoscopic surgery.
  • Surgical visualization systems.
  • Arthroscopic bone tunneler and other orthopedic surgical instrumentation.
  • Brain stimulation to treat multiple disorders.

See link for a month-by-month listing of the technologies at companies in the Medtech Startups Database.

New technologies at medtech startups, October 2014

Below is a list of the technologies under development at medical technology startups recently identified and included in the Medtech Startups Database.

  • Prosthetic disc nucleus in spine surgery.
  • Device and non-device technologies based on dynamics of blood flow.
  • Magnetic and fluorescent technology point-of-care device to detect heart attack.
  • Technologies for tissue reconstruction.
  • Adult stem cell therapy in orthopedics, aesthetics, and chronic diseases (diabetes, COPD, heart disease, multiple sclerosis, stroke/cerebrovascular disease).
  • Vagus nerve stimulation for neuromodulation treatment of various inflammatory autoimmune diseases.
  • Surgical devices including for endoscopic access closure.
  • Device to measure sympathetic nerve activity and produce ECG.
  • Simultaneously track electrical measures that indicate brain, heart, optical and musculoskeletal activity.
  • Needle-free pediatric withdrawal of blood.
  • Ventilation systems for improved delivery of gas, moisture and nebulized medication.
  • Broadly focused medical technology company active in osteoarthritis, cardiovascular, stroke, diabetes, infection control and spine surgery.

For a historical listing of technologies at medtech startups, see link.

Funding in medical technology, October 2014

Funding for medical technologies in October 2014 totaled $332 million, led by the $59 million funding of Ivantis, Inc., and the $55 million funding of PureTech.

Below are the top fundings for the month:

Company, funding Product/technology
Ivantis, Inc., has raised $58.87 million of a $71.37 million round of fundng according to a regulatory filing Stent-based treatment to lower intraocular pressure in glaucoma
PureTech has raised $55 million in a round of funding according to the company Medical device and other technologies spanning treatments in immunology, metabolism, neuroscience, drug delivery and consumer digital health
VytronUS, Inc., has raised $31.6 million in a Series B round of funding according to the company Integrated imaging and ultrasound ablation for treatment of cardiac arrhythmias
Respicardia, Inc., has raised $25.09 million in a round of funding according to a regulatory filing Electrical pulse-based implant treatment for sleep apnea
Magnus Life Science (Magnus Life Ltd) has raised £15.5 million ($24.96 million) in a round of funding according to regulatory filing Device and non-device technologies based on dynamics of bloodflow
Medrobotics Corp. has raised $20 million in a preferred stock offering according to the company Computer-assisted access and visualization system for minimally invasive robotic surgery

For the complete list of medtech fundings in October 2014, see link. For a historical list of the fundings in medtech, by month, since 2009, see link.

New Medical Technologies at Startups, September 2014

Below is a list of new technologies under development at medtech startups recently identified and included in the Medtech Startups Database:

  • Robotics for ophthalmic surgery.
  • Dynamic force generation for bone repair.
  • Neursurgical brain simulation system.
  • Orthopedic technologies including pedicle screw that does not require a guide wire.
  • Synthetic bone graft materials.
  • Minimally invasive mitral valve replacement.

For a historical listing of the technologies under development at medtech startups, see link.

New Technologies Under Development at Medtech Startups, August 2014

Below is a list of the technologies under development at newly identified medtech startups and included in the Medtech Startups Database.

  • Technology for the repair of rotator cuff tears.
  • Technologies for intravenous cannulation and phlebotomy, and an otorhinoscope.
  • Implant for the treatment of urinary incontinence.
  • LED (light) treatment of acute, dry macular degeneration.
  • Esophageal cooling device to manage patient temperature.
  • Surgical robotics.
  • Patient positioning system for orthopedic surgery.
  • Device to treat macular degeneration by delivering microcurrent to the eye.

For a historical listing of medtech startup technologies included in the database, see link.

Effective technologies for wound hemostasis, sealing and closure

See the pending 2014 Report #S192, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2013-2020″.

Tourniquet, pressure and sutures have been used for controlling excessive bleeding during surgical procedures for many hundreds of years. Fibrin sealants represented a revolution in local hemostatic measures for both bleeding and nonbleeding disorders. Fibrin sealant has the potential to provide life-saving control of excessive bleeding in many critical surgical operations and during a number of elective procedures. The terms “sealant” and “glue” are frequently used interchangeably in the surgical context, but there is actually a difference in adhesive strength between sealants, pioneered by fibrin products (sometimes homemade) and the later, stronger glues of which cyanoacrylate-based products are the most common.

In order for a sealant to be effective, the product should meet several parameters, depending upon the application. Among these are:

  • Ability to close the wound
  • Strength of bond
  • Speed of curing
  • Protection of the wound from infection
  • Low surface friction
  • Breathability in order to aid healing
  • Lack of adverse side effects to skin and internal tissues
  • Cost-effectiveness
  • Ease of handling

Fibrin and other sealant products have been approved and used outside the United States for many years and their use has created strong awareness of their surgical and economic benefits in Europe, Latin America and Asia. As a result, many such products have been marketed in these regions for 20 years or more, and have been developed for a variety of surgical uses. In the U.S., these products were initially approved as hemostatic adjuncts to suturing. They are increasingly being used for sealing of tissues, but their use beyond simple hemostasis (i.e., as sealants and low-strength glues) lags that of markets outside the U.S.

Despite the development of novel sutures (e.g., resorbable), endoscopically applied clips and other innovations, fibrin sealants will remain a versatile option available to surgeons to achieve hemostasis and sealing of wounds (alone or adjunctively with sutures/staples). Their clinical track record, biocompatibility and ready availability match high demand. Their limitation in adhesive strength, however, does put some limit on their sales potential, since significant demand exists for tight sealing and strong bonding of tissues under stress, such as in lung and bowel resections, cardiovascular and other anastomoses and adhesion of muscle, that go beyond what fibrin sealants can achieve. For this reason, other naturally-occuring “bioglues” are under development that will achieve tighter tissue bonds than fibrin sealants, but without the toxic effects of cyanoacrylates (“superglues”).

There are more than 30 companies worldwide developing fibrin sealants and driving a market that will exceed $2.2 billion by 2017.

sealants-regional-forecast

 Source: MedMarket Diligence, LLC; Report #S190. (This report is being updated by the pending 2014 Report #S192.)

For complete analysis of the global market for fibrin sealants, see the MedMarket Diligence Report #S190, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2017.”

Medical technologies and recently identified startups (June 2014)

New medical technologies under development at recently identified startups span ophthalmology, gastroenterology, cardiology, spine surgery, orthopedics, patient monitoring and surgical instrumentation.  Below are the technologies at the recently identified medtech startups that have been included in the Medtech Startups Database.

  • Intraocular lens for presbyopia.
  • Portable, wireless EKG device.
  • Tissue engineering in peripheral and central nervous system injury.
  • Micro transtympanic drug delivery to the ear.
  • Diagnosis of functional GI disorders.
  • Spinal implants and instrumentation systems.
  • Surgical suction devices.
  • Calcium phosphate bioceramic implants for bone defects.
  • Intervertebral fusion cage.
  • Monitoring of neural activity during sedation.
  • Surgical instrument positioning systems for minimally invasive and robotic surgery.
  • Critical care monitoring technologies.

For a historical listing of medical technologies under development at startups, see link.